Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma
- First Posted Date
- 2012-12-12
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT01747876
- Locations
- 🇺🇸
Childrens Healthcare of Atlanta Dept of Oncology, Atlanta, Georgia, United States
🇺🇸Dana Farber Cancer Institute SC-7, Boston, Massachusetts, United States
🇺🇸Cincinnati Children's Hospital Medical Center Dept of Oncology, Cincinnati, Ohio, United States
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation
- First Posted Date
- 2012-12-07
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 59
- Registration Number
- NCT01744665
- Locations
- 🇺🇸
Compassionate Care Research Group Inc CCCMG, Fountain Valley, California, United States
🇺🇸Michigan State University / Breslin Cancer Center Breslin Cancer Center (3), Lansing, Michigan, United States
🇺🇸Hackensack University Medical Center John Theurer Cancer Center, Hackensack, New Jersey, United States
An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis
- Conditions
- Oestrogen Receptor Positive Advanced Breast Cancer
- Interventions
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT01743560
- Locations
- 🇬🇧
Novartis Investigative Site, Portsmouth, United Kingdom
A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.
- Conditions
- Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
- Interventions
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 620
- Registration Number
- NCT01743989
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
Compare the Effect of a Remote Monitoring System Using the EXACT Tool to Reduce Hospitalizations Due to Chronic Obstructive Pulmonary Disease (COPD) Exacerbations. EXACT = Exacerbations of Chronic Pulmonary Disease Tool.
- Conditions
- Remote Patient Monitoring in COPD Patients
- Interventions
- Device: Remote Patient MonitoringOther: Usual care
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2020-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 118
- Registration Number
- NCT01744028
- Locations
- 🇸🇪
Novartis Investigative Site, Östersund, Sweden
Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
- First Posted Date
- 2012-12-05
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 155
- Registration Number
- NCT01742299
- Locations
- 🇺🇸
University of California LA, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Sidney Kimmel CCC At JH, Baltimore, Maryland, United States
Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
- First Posted Date
- 2012-12-05
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 83
- Registration Number
- NCT01742286
- Locations
- 🇺🇸
Dana Farber Cancer Institute Dept of Onc, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering SC - 7, New York, New York, United States
🇬🇧Novartis Investigative Site, Sutton, Surrey, United Kingdom
Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.
- Conditions
- Advanced Hepatocellular Carcinoma With c-MET Dysregulation
- Interventions
- Drug: INC280
- First Posted Date
- 2012-11-30
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT01737827
- Locations
- 🇹🇭
Novartis Investigative Site, Bangkok, Thailand
An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)
- Conditions
- Thalassemia, Non-transfusional-dependent Thalassemia (NTDT), Myeloplastic Dysplasia (MDS), Other Anemia
- Interventions
- Device: MRI scan
- First Posted Date
- 2012-11-29
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 243
- Registration Number
- NCT01736540
- Locations
- 🇦🇺
Novartis Investigative Site, Perth, Western Australia, Australia
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
- Conditions
- Chronic Myelogenous Leukemia (CML)Metastatic Gastrointestinal Stromal Tumors (GIST)Acute Lymphoblastic Leukemia (ALL)Receptor Tyrosine Kinase (KIT) Mutated Melanoma
- Interventions
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 57
- Registration Number
- NCT01735955
- Locations
- 🇬🇧
Novartis Investigative Site, Newcastle upon Tyne, United Kingdom